{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093991","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.979621+00:00","generated_at":"2026-05-31T11:18:11.372093+00:00","sec_items":["2.02","9.01","5.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs","bullets":["Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.","Cash, equivalents & marketable securities $99.3M; sufficient into H2 2025; $45M SVB credit facility available, undrawn.","TN-201 received FDA Rare Pediatric Disease Designation for MYBPC3-associated HCM; interim Phase 1b data expected H2 2024.","TN-401 cleared by UK MHRA to start Phase 1b; 84% of screening volunteers eligible based on low AAV9 antibodies.","CFO Leone Patterson departing Aug 14; CEO Faraz Ali interim PFO; Chihiro Saito interim PAO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093991","json":"https://secwatch.observer/filing/0000950170-24-093991.json","markdown":"https://secwatch.observer/filing/0000950170-24-093991.md","text":"https://secwatch.observer/filing/0000950170-24-093991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/tnya-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:18:11.372093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0caf3310e4","claim":"Chihiro Saito was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..","evidence_excerpt":"Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"256b1eaebd","claim":"Faraz Ali was appointed as Interim Principal Financial Officer at Tenaya Therapeutics, Inc..","evidence_excerpt":"Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fdc49b08d5","claim":"Leone Patterson departed as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..","evidence_excerpt":"Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceasing to be"},{"label":"Role","value":"Chief Financial and Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}